Plain-English answer
U.S. hospital payment is payer-specific and contract-heavy, while China is moving from fee-for-service and public hospital revenue dependence toward DRG, DIP, procurement, and insurance-fund discipline. Both systems use payment reform to control hospital behavior.
How the U.S. side works
U.S. hospitals face Medicare prospective payment, Medicaid payment, commercial contracts, uncompensated care, value-based programs, and site-of-care pricing. This produces substantial variation by payer, state, plan design, provider market, coding route, and contracted economics. In practice, a national U.S. answer often fails unless it is narrowed to a payer and setting.
How the China side works
Chinese hospitals face public hospital governance, DRG and DIP pilots and expansion, global budget discipline, drug and device procurement, and medical service pricing reform. This produces a different kind of variation: national policy may define the direction, but provinces, municipalities, hospitals, procurement rules, and local insurance funds shape practical access.
Side-by-side comparison
| Dimension | United States | China | Analytical implication |
|---|---|---|---|
| Primary control mechanism | Contracts, benefit design, coding, coverage, networks, and provider market power. | Administrative policy, public hospital hierarchy, reimbursement lists, procurement, and local implementation. | U.S. strategy must segment by payer and channel; China strategy must segment by policy lever, locality, and hospital role. |
| Operating variation | High variation by payer, state, employer, provider system, and plan. | High variation by city, province, hospital tier, insurance fund, and implementation rule. | Neither country can be analyzed accurately with one national average. |
| Commercial pathway | Regulatory clearance, coding, coverage, reimbursement, contracting, and institutional adoption. | Regulatory approval, reimbursement status, procurement, hospital listing, and local affordability. | Approval is only one step in both countries. |
Current evidence and sources
Hospital payment is one of the clearest examples of similar labels hiding different systems. The United States uses Medicare prospective payment, commercial contracts, Medicaid rules, supplemental payments, and site-specific billing dynamics. China is moving public insurance payment away from fee-for-service through DRG and DIP pilots, but implementation is deeply local and interacts with public-hospital budgets, medical-service pricing, drug procurement, and hospital performance incentives.
U.S. anchor
CMS describes Medicare IPPS as predetermined payment by MS-DRG for inpatient discharges, but that is only one payer's method inside a broader multi-payer hospital revenue model.
China reform direction
China's NHSA three-year DRG/DIP action plan signals a national push to change provider incentives, standardize payment groups, and build payer-management capacity.
Implementation evidence
Recent DIP research in Guangzhou illustrates that payment reform effects need to be measured locally because hospital behavior, case mix, and patient cost sharing can move differently across cities.
Selected sources
Research-based interpretation
In the United States, payment varies by payer contract; in China, the key issue is how state payment reform changes hospital incentives and local implementation. The comparison should therefore be used as a decision framework, not as a static ranking of which system is better. Each system solves some problems by creating other constraints.
Comparison caution
Treating DRGs or fee-for-service as identical instruments across systems. A stronger analysis names the mechanism, the decision-maker, the affected patient group, and the payment or governance pathway.
How to read the comparison
Define the unit of comparison
Compare payer to payer, hospital to hospital, regulator to regulator, or workflow to workflow, not country label to country label.
Identify the control mechanism
The United States often uses contracts, coding, coverage, networks, and market power; China often uses administrative policy, public hospitals, procurement, and local implementation.
Separate formal rule from operating reality
Both systems contain gaps between written policy and practical access, adoption, affordability, and institutional behavior.
Strategic meaning
For cross-border healthcare strategy, this comparison matters because product-market fit is institutional. A technology, drug, device, care model, or partnership that works in one country may fail in the other if it does not fit the payment, procurement, regulatory, data, and provider-behavior environment.